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Background: There is a large body of evidence demonstrating long-lasting protective effect of 
each full-term pregnancy (FTP) on the development of breast cancer (BC) later in life, a phe-
nomenon that could be related to both hormonal and immunological changes during pregnancies. 
In this work, we studied the pregnancy-associated differences in peripheral blood gene expres-
sion profiles between healthy women and women diagnosed with BC in a prospective design.
Methods: Using an integrated system epidemiology approach, we modeled BC incidence as a 
function of parity in the Norwegian Women and Cancer (NOWAC) cohort (165,000 women) and 
then tested the resulting mathematical model using gene expression profiles in blood in a nested 
case–control study (460 invasive case–control pairs) of women from the NOWAC postgenome 
cohort. Lastly, we undertook a gene set enrichment analysis for immunological gene sets.
Results: A linear trend fitted the dataset precisely showing an 8% decrease in risk of BC for each 
FTP, independent of stratification on other risk factors and lasting for decades after a woman’s last 
FTP. Women with six children demonstrated 48% reduction in the incidence of BC compared to 
nulliparous. When we looked at gene expression, we found that 756 genes showed linear trends 
in cancer-free controls (false discovery rate [FDR] 5%), but this was not the case for any of the 
genes in BC cases. Gene set enrichment analysis of immunologic gene sets (C7 collection in 
Molecular Signatures Database) revealed 215 significantly enriched human gene sets (FDR 5%).
Conclusion: We found marked differences in gene expression and enrichment profiles of immu-
nologic gene sets between BC cases and healthy controls, suggesting an important protective 
effect of the immune system on BC risk.
Keywords: breast cancer, Norwegian Women and Cancer Study, gene expression, parity, semi-
allograft, hormones, pregnancy
Introduction
Each pregnancy represents a unique and remarkable challenge to the mother’s immune 
system, as her body must accept and carry a fetus to term without immune rejection. 
Immunological tolerance during pregnancy is necessary for women’s bodies to accept 
the fetus.1,2 This obligate tolerance has been observed for many years, and because 
of it, each fetus can be seen as a different semi-allograft. Interestingly, “immune eva-
sion”, which consists of some similar immunological changes, was included as another 
hallmark of cancer,3 and researchers have recognized some common characteristics 
between these two highly different biological processes.4–7 Looking at this, it seems 
paradoxical that increasing number of full-term pregnancies reduces the risk of breast 
cancer (BC) in women.8,9 Some studies have even shown a protective effect up to eight 
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or nine children.8 However, neither spontaneous nor induced 
abortions confer the same risk reduction.10,11
The role of hormones is well established in both preg-
nancy and tumorigenesis; however, the influence of hormonal 
fluctuations associated with pregnancy on the cancer develop-
ment in a long-term perspective remains unclear.12,13 High, 
changing levels of hormones such as estrogens, gestagens, 
and human chorionic hormone initiate and support immuno-
logical tolerance during pregnancy,14 whereas the high levels 
of estrogens and progestins found in oral contraceptives and 
hormone replacement therapy are classified as carcinogens.15
We have previously shown that blood gene expression 
profiles differ between women with BC and BC-free con-
trols, both at time of diagnosis16 and during the years prior 
to diagnosis.17 Additionally, in a recent study, we compared 
gene expression in blood and breast tumor tissue.18 We 
revealed some similarities in expression profiles mainly for 
immunogenic tumors; however, we demonstrated that there 
is no obligate common gene expression pattern.
Here, we aim to explore changes in blood gene expres-
sion in women with BC and cancer-free controls according 
to number of full-term pregnancies (FTPs).
Methods
Norwegian Women and Cancer 
(NOWAC) study
The NOWAC study19 is a national population-based study 
in which a random sample of women living in Norway was 
recruited starting in 1991. Among the 172,748 women invited 
to participate, 165,227 women replied to at least one question-
naire and make up the study population. Death and emigration 
status of these women were updated through linkage to the 
Cause of Death Registry at Statistics Norway and Central 
Population Registry, respectively. Information on parity was 
taken from the NOWAC questionnaires. The date of entry 
into the present study was set as the date of the first question-
naire answered. The exit date from NOWAC was determined 
either by the date of cancer diagnosis or end of follow-up 
(2013/12/31). The NOWAC postgenome cohort consisted of 
48,692 women randomly sampled from the whole NOWAC 
study, born in 1943–1957, with a blood sample buffered to 
preserve the gene expression profile (PAXgene Blood RNA 
system; Preanalytix/Qiagen, Hilden, Germany). The NOWAC 
postgenome biobank contained blood samples from women 
taken by local physicians and mailed overnight to the study 
center in Tromsø. The blood was collected in 2003–2006.20 
BC cases that were diagnosed in 2003–2009 were identified 
through linkage to the National Cancer Registry of Norway. 
Altogether 546 cases were identified prospectively, ie, devel-
oped BC after blood sample donation.
For each BC case, a control from the NOWAC post-
genome cohort was assigned, matched by time of blood 
sampling and year of birth, to be analyzed together with the 
case. The controls were used to establish the average (mean) 
gene expression in individuals without cancer and to serve 
as the basis for exposure-adjusted analyses. The expression 
level of a gene not involved in the carcinogenic process 
varied depending on day-to-day changes in exposures such 
as environment and nutrition, resulting in random fluctua-
tions of the difference in gene expression between cases and 
matched controls around a population-average constant over 
time. On the other hand, the difference in the expression of 
genes related to different stages of the carcinogenic process 
varied over time in a nonrandom way, thus exhibiting a non-
random trend. Moreover, the changes in the expression of 
genes related to the carcinogenesis could be complicated by 
other effects caused by exposure to carcinogens.
Laboratory procedures
All extraction and microarray services were provided by the 
Genomics Core Facility, Norwegian University of Science 
and Technology, Trondheim, Norway. To control for tech-
nical variability such as different batches of reagents and 
kits, day-to-day variations, microarray production batches, 
and effects related to different laboratory operators, each 
case–control pair was kept together throughout all extraction, 
amplification, and hybridization procedures. RNA extraction 
was performed using the PAXgene Blood mRNA Isolation 
kit (Preanalytix/Qiagen) according to the manufacturer’s 
instructions. RNA quality and purity were assessed using 
the NanoDrop ND 8000 Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA) and Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA), respectively. 
RNA amplification was performed on 96-well plates using 
300 ng of total RNA and the Illumina TotalPrep-96 RNA 
Amplification Kit (Ambio, Inc., Austin, TX, USA). The 
amplification procedure consisted of reverse transcription 
with a T7 promoter and ArrayScript, followed by a second-
strand synthesis. In vitro transcription with T7 RNA poly-
merase using a biotin–nucleoside triphosphates mix produced 
biotinylated cRNA. All case–control pairs were run on either 
the IlluminaHumanAWG-6 version 3 expression bead chips 
or the HumanHT-12 version 4 expression bead chips. Outli-
ers were excluded after visual examination of dendrograms, 
principal component analysis (PCA) plots and density plots. 
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Parity and gene expression in breast cancer
excluded if their laboratory quality measures were below 
given thresholds (RNA integrity number value <7, 260/280 
ratio <2, 260/230 ratio <1.7, and 50 < RNA < 500).
Statistical methods
The first stage of the analysis was to explore the relationship 
between full-term pregnancies and BC in the whole NOWAC 
cohort. Based on person-years, the percentage change in 
incidence rates of BC for each additional child was calcu-
lated by using a Poisson linear regression. Each covariate 
was analyzed separately in a stratified analysis with test for 
interactions using the Wald test. A Cox proportional semipa-
rametric hazard analysis with attained age as follow-up was 
used for estimating the overall effect of potential confounders.
Then, gene expression profiles were analyzed for BC 
cases and controls using microarray technology. The dataset 
with 30,046 probes for each individual was preprocessed 
as previously described.21 The dataset was background cor-
rected using negative control probes, log
2
 transformed using 
a variance stabilizing technique,22 and quantile normalized. 
Data from the two Illumina chips (HumanWG-6 v3 and 
HumanHT-12 v4) were combined on identical nucleotide 
universal identifiers.23 We retained probes present in at least 
70% of the individuals. If a gene was represented with more 
than one probe, the average expression level of the probes was 
used as the expression for the gene, resulting in a dataset with 
8155 genes. The probes were translated to genes using the 
lumiHumanIDMapping database.24 Finally, the differences in 
the log
2
 gene expression for each case–control pair were com-
puted and used in the statistical analyses. We then excluded 
79 case–control pairs in which the case was diagnosed with 
in situ BC and seven pairs in which the controls were diag-
nosed with BC before the end of follow-up in 2014. The 
final preprocessed dataset included 460 case–control pairs.
A nested case–control design was chosen in order to 
reduce batch effects in the laboratory. In PCA plots, we 
observed no batch effects in the data that were obtained after 
we computed differences in log2 gene expression between 
cases and controls. We used the Bioconductor R-package 
Limma (linear models for microarrays) to identify the genes 
that were influenced by parity.25 In the linear model, the 
responses were the differences in the log
2
 gene expression 
for each case–control pair, while we included the parity of 
the control and the parity of the case as covariates. In the 
analyses, we merged parities 1–3 and 4–6 so that the parity 
data consisted of three different values: 0, 1–3, and 4–6. The 
merging was made in order to reduce the effect of the highest 
parities. The distribution of parities for cases and controls 
included in this study is shown in Table S1. We identified 
gene sets that were influenced by parity using Limma in the 
same way as we did for individual genes by using enrichment 
scores for gene sets instead of differences in the log
2
 gene 
expressions as responses in the linear model. The enrichment 
scores for gene sets were obtained from the differences in 
log
2
 gene expressions using the Bioconductor R-package 
gene set variation analysis (GSVA).26
Ethics approval and consent to 
participate
The NOWAC study was approved by the Norwegian Data 
Inspectorate and the Regional Ethical Committee of North 
Norway (REK). The study was conducted in compliance with 
the Declaration of Helsinki, and all participants gave written 
informed consent. The linkages of the NOWAC database to 
national registries such as the Cancer Registry of Norway 
and registries on death and emigration were approved by the 
Directorate of Health. The women were informed about these 
linkages. Furthermore, the collection and storing of human 
biological material was approved by the REK in accordance 
with the Norwegian Biobank Act. Women were informed in 
the letter of introduction that the blood samples would be 
used for gene expression analyses.
Results
Reduction of BC risk after full-term 
pregnancies
Our first step was to estimate the mathematical relationship 
between parity and BC incidence in the complete NOWAC 
cohort, which consisted of 165,227 participants and 6536 
registered incident BC cases identified through linkage to the 
Cancer Registry of Norway. Increasing parity was related to 
less BC in mothers, less use of hormone replacement therapy, 
larger body mass index (BMI), earlier first birth, more breast 
feeding, and less use of oral contraceptives (Table 1). Among 
both premenopausal and postmenopausal women, a regular 
decrease in incidence rates was found (Figure 1 and Table S2), 
and in linear regression analyses of BC incidence in the 
complete NOWAC cohort, each new pregnancy conferred a 
strong linear reduction in the absolute risk (8.0%; Figure 1). 
This led to an observed reduction of 48% for a woman with 
six children.
Differences in BC incidence rates were of the same order 
between nulliparous and uniparous women and for women 
with five or six children, illustrating an additive effect. The 
linearity of BC incidence was equally clear regardless of 
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but postmenopausal women had higher BC incidence rates 
(Figure 1). Stratification on all risk factors (current use 
of hormone replacement therapy, BMI, age at first birth, 
breastfeeding, ever use of oral contraceptives, and maternal 
history of BC) revealed the same linear patterns (Table S3). 
There were no significant interactions between different 
strata of the risk factors (none in the Wald test). Using the 
Cox’s multivariate hazard model adjusted for the same risk 
factors (taken from Table S3), the crude estimated relative 
risk (RR) in women with six children versus nulliparous 
women was 0.50 (95% CI 0.37–0.66) and adjusted RR was 
0.49 (95% CI 0.36–0.68), similar to the ones derived from 
Poisson regression analysis (Table S4).
Differential pregnancy-associated blood 
gene expression between cases and 
controls
This linear relationship independent of other covariates was 
then used to test the hypothesis that blood gene expression of 
some genes increased or decreased linearly according to parity.
An overall analysis without parity status showed no sig-
nificant differences in expressed genes between cases and 
controls. When we added one parity variable for the cases 
and one for the controls in the model, we found a significant 
linear relationship between log gene expression and parity for 
756 genes in BC-free controls, but we found no such relation-
ship in BC cases (false discovery rate [FDR] 5%). Among the 
controls, 96 of 756 significant genes had at least 5% change 
per child (91 were upregulated and five were downregulated) 
and four genes had at least 10% change per child (all were 
upregulated). A description of potential carcinogenic effects 
in BC of the ten top significant genes showed (Table 2) that 
four of them are tumor promoter genes and one is a tumor 
suppressor gene; however, the function of five significant 
genes was unknown.
Gene set enrichment analysis
Table 3 demonstrates the results of gene set enrichment 
analysis. We identified 588 gene sets from the C7 collection 
in Molecular Signatures Database (MSigDB; http://software.
broadinstitute.org/gsea/index.jsp)27 that were significantly 
enriched when the parity of the controls varied (FDR 5%). 
Table 1 Description of the entire study population according 
to parity
Characteristics Parity (number of 
children)
0 1–2 3–4 5–6
Maternal history of BC 5.9 5.2 5.2 4.5
Current use of hormone replacement 
therapy
17.4 17.1 14.7 12.7
BMI <25 kg/m2 58.7 58.5 53.7 43.8
Age at first birth <25 years NA 53.2 70.8 82.2
Years of lactation
Never 100.0 7.8 4.1 3.1
<2 years NA 88.3 69.5 47.8
2+ NA 3.8 26.4 49.1
Ever use of oral contraceptives 47.6 59.6 52.7 37.5
Note: Numbers represent a percentage of women within the corresponding parity 
category.
Abbreviations: BC, breast cancer; BMI, body mass index; NA, data not available.
Figure 1 BC incidence rates in the NOWAC study, 1991–2013.
Note: 95% CIs and linear trends according to parity (A) and parity and menopausal status (B; n = 165,227, BC cases = 6,536, PY = 2,390,385).
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Parity and gene expression in breast cancer
Experimentally produced gene sets were submitted to 
MSigDB from researchers using both in vivo and in vitro 
materials, as well as both human cells or tissues and animal 
models. Of our 588 enriched gene sets, 215 were derived from 
human data and 373 were derived mostly from mouse data.
Detailed characterization of the top 10 gene sets from 
each species showed a discrepancy in the tissues analyzed: 
blood and cord blood in humans versus bone marrow and 
spleen in mice (Tables 4 and S5). We had information on 
gender for only one of the top 10 human gene sets and four 
of the mouse gene sets (after contacting main authors of the 
associated publications). None of the MSigDB gene sets from 
either humans or mice included information on the number 
of full-term pregnancies (Table 4).
Discussion
We suggest that our unexpected finding of no changes in gene 
expression levels from circulating immune-competent cells in 
BC cases as opposed to parity-dependent changes in healthy 
women might be linked to the long-term immune-related 
 protection against BC conferred by semi-allograft experi-
ence of each pregnancy. Our findings demonstrating the 8% 
decrease in BC risk for each birth correspond well to a number 
of previously published studies.8,9
The systems epidemiology approach we used is based on 
an integrated analysis in the same cohort; first, hypotheses 
describing the mathematical relationship between parity and 
BC incidence in the whole NOWAC study are explored. The 
findings were that the linear relationship between parity and 
BC could be described as independent of other risk factors. 
Then, this hypothesis was tested using gene expression pro-
files obtained from the postgenome biobank of NOWAC. 
Consequently, we reduced the number of multiple testing 
in the gene expression analysis and the potential for false-
positive findings.
In a recent analysis of interactions between gene expres-
sion in BC tissues and blood samples nested in the NOWAC 
postgenome study,18 we found that genes expressed in tumors 
and used as markers are not necessarily expressed in a similar 
manner in blood. Not surprisingly, tumors were enriched 
Table 2 Top 10 single genes ranked according to q-value with logFC and their role in BC
Gene ID logFCa q-valueb Role in BC Function
CNOT8 0.064 0.013 TP Involved in translation and transcription regulation
ZRANB2 0.140 0.013 NA Protein regulating alternative splicing; exact function is unknown
TFRC 0.080 0.013 TP Required for transfer of iron into cells from transferrin
CD47 0.105 0.013 TP Involved in many cellular processes including proliferation, migration, and apoptosis
PSORS1C1 -0.039 0.013 NA Function is not known. Mutations are associated with psoriasis, systemic sclerosis, and 
rheumatoid arthritis
EML4 0.073 0.013 NA Protein involved in microtubule formation
FKBPL -0.027 0.013 TS A wide range of functions including cell cycle regulation, trafficking, and angiogenesis 
inhibition
HACL1 0.044 0.013 NA Exact role is unclear. Catalyzes a carbon–carbon cleavage reaction. Involved in lipid 
metabolism
PPP1R2 0.093 0.017 NA Serine/threonine phosphatase. Function is not known
LPIN1 0.075 0.017 TP Protein controlling the metabolism of fatty acids. Transcriptional coactivator
Notes: alogFC is the estimated log-fold change in gene expression when the parity increases with one. bq-value is an FDR-adjusted p-value.
Abbreviations: BC, breast cancer; FDR, false discovery rate; NA, data not available; TP, tumor promoter; TS, tumor suppressor.
Table 3 Gene set enrichment analyses for all gene sets included in MSigDB
Collection name All gene sets Significant gene sets (FDR 5%)
Total Human Other Total Human Other
C1: positional gene sets 326 326 0 75 75 0
C2: curated gene sets 4729 3750 979 280 229 51
C3: motif gene sets 836 835 1 22 0 22
C4: computational gene sets 858 857 1 217 217 0
C5: gene ontology gene sets 6166 6162 4 0 0 0
C6: oncogenic signatures 189 144 45 42 35 7
C7: immunologic signatures 4872 1844 3028 588 215 373
Note: In non-human gene sets, mice are the dominant species (http://software.broadinstitute.org/gsea/msigdb/index.jsp MSigDB v5.2). Copyright ©2018. Dove Medical Press. 
Reproduced from Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. 
Proceedings of the National Academy of Sciences. 2005;102(43):15545–50.27.27
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for genes related to cancer hallmarks, while in blood, the 
genes represented either general cellular or immune-related 
processes.
Currently, there is no unifying concept explaining 
mechanism of pregnancy-related BC protection. Yet, four 
main theories may be underlined: decreased number of 
mammary stem cells, changes in circulating hormone levels, 
differentiation of breast epithelial cells, and altered estrogen 
responsiveness.28 Notably, most of these theories are based 
on studies focusing on the local changes in the mammary 
gland, while we used blood samples as the source of data, 
thus looking at systemic processes.
The single-gene analysis revealed a set of genes linearly 
changing expression after pregnancies in controls. Almost all 
of these genes were upregulated. This parity-dependent effect 
was nonsignificant when we compared all cases and controls 
without taking parity status into account. A possible explana-
tion could be the low parity in the study population with two 
children as the median value. Of the top ten significant genes, 
four upregulated genes were known to be related to breast 
carcinogenesis.29–32 Similar to our results, one study found 
lower levels of TFRC in plasma of BC cases compared to 
controls.33 However, the overall meaning of these expression 
changes in healthy women is uncertain.
Previously, Rotunno et al34 demonstrated the significant 
enrichment of inflammatory and immune response genes in par-
ous women compared to nulliparous. In our gene set enrichment 
analysis, we observed significant enrichment of numerous gene 
sets related to the immune system (C7 collection in MSigDB). It 
is nearly impossible to make an unambiguous conclusion from 
these results due to the complexity of gene sets’ data and lack 
of essential information in gene sets’ description (eg, we were 
unable to ascertain the gender of blood donors for the major-
ity of human experiments even after contacting the authors of 
publications). Nevertheless, we observed a clear interspecific 
difference between components of the immune system: the 
gene sets were related to (in mice, most of the gene sets were 
of innate immunity origin, while in humans, they were of 
adaptive origin) and between the sources of the cells for the 
experiments. While the latter can be explained by technical and 
ethical considerations, the former raises yet another concern on 
the validity of results obtained in animal models.35–39
Pregnancy and cancer share multiple characteristics 
including proliferation, invasion, neoangiogenesis, and 
Table 4 Top 10 gene sets for humans and mice with information on experimental design
geneSetID scoreDiffa FDR  
(q-value)




GSE3982 0.023 0.027 Cord blood I NA Macrophages NA
GSE2770 -0.026 0.027 Cord blood A NA CD4+ T cells NA
GSE16385 0.047 0.027 Blood I NA Monocytes NA
GSE1460 0.034 0.027 Cord blood
Blood
A NA CD4+ T cells NA
GSE13411 -0.035 0.027 Spleen A NA B cells M, F
GSE2770 0.027 0.027 Cord blood A NA CD4+ T cells NA
GSE29618 -0.029 0.027 Blood I NA DC NA
GSE17974 0.028 0.027 Cord blood A NA CD4+ T cells NA
GSE2770 -0.028 0.027 Cord blood A NA CD4+ T cells NA
GSE29615 0.038 0.027 Blood I, A NA PBMCs NA
Mouse
GSE17721 0.018 0.027 Bone marrow I NA DC F
GSE14769 0.032 0.027 Bone marrow I NA Macrophages NA
GSE3691 0.037 0.027 Various tissues I NA DC F
GSE37301 0.035 0.027 Bone marrow I, A NA HSCs, CLPCs NA
GSE32034 0.028 0.027 Various tissues I NA Monocytes M
GSE17721 0.026 0.027 Bone marrow I NA DC F
GSE21063 0.036 0.027 Spleen A NA B cells NA
GSE11924 -0.029 0.027 Spleen A NA CD4+ T cells NA
GSE28237 0.035 0.027 Spleen A NA B cells NA
GSE13547 0.034 0.027 Spleen A NA B cells NA
Note: ascoreDiff is the estimated change in enrichment score when the parity increases with one.
Abbreviations: A, adaptive immune system; CLPCs, common lymphoid progenitor cells; DC, dendritic cells; F, female; FDR, false discovery rate; HSCs, hematopoietic stem 
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Parity and gene expression in breast cancer
modulation of local and systemic immune response.4 Indeed, 
in our study, we observed that women with a high parity have 
a higher expression of tumor promoter genes and a lower 
expression of tumor suppressor genes; therefore, we propose 
that the body might experience each pregnancy as a “pseudo 
cancer”. It is possible to suggest that some pregnancy-related 
processes may have common genetic signatures and protein 
expression profile with initial stages of breast tumor forma-
tion. Being securely controlled by a variety of local and 
systemic mechanisms during pregnancy, the immune system 
does not respond to the changes in breast tissue, while stor-
ing memory and effector cells. Later, these cells can initiate 
rapid and extensive response against cancer cells during the 
early stages of carcinogenesis. This phenomenon of long-term 
storage of various subsets of antigen-experienced immune 
cells after pregnancies has previously been described.40,41 
Slight expressional differences in each pregnancy expand 
the pool of antigen-specific immune cells, thus increasing 
protective effect with the number of pregnancies. Recently, 
Krause et al42 published an experimental study confirming 
our hypothesis.
Our findings of an impaired immune surveillance in 
BC patients opposed to healthy women may generate novel 
approaches to immunotherapy based on the natural mecha-
nisms involved in amplified protection against BC with 
repeated pregnancies. Deciphering of these mechanisms 
could significantly improve response rate of BC patients to 
immunotherapy, which at present remains poor.43–45
The major weakness of the study is the lack of statistical 
power for the gene expression analyses. However, this was 
compensated by the strict hypothesis testing approach. The 
strength of the design is the complete follow-up on cancer, 
emigration, and mortality based on a unique national birth 
number. The external validity of the parity data in NOWAC 
was found to be excellent in a linkage study based on infor-
mation from the fertility register in Statistics Norway.46
Conclusion
To our knowledge, this is the first study revealing the 
involvement of the immune system in parity-associated BC 
protection with the use of systems epidemiology approach. 
Owing to descriptive study design, it is not possible to hypoth-
esize the exact mechanisms responsible for the pregnancy- 
associated protection from BC using data obtained in this 
work. Our focus on systemic rather than on local changes 
may provide the scientific community with a fresh view on 
the biology of BC and may become a foundation for future 
research.
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Parity and gene expression in breast cancer
Supplementary materials
Table S1 Distribution of parities for the cases and controls
Parities
0 1 2 3 4 5 6 Sum
Cases 69 67 208 83 29 4 0 460
Controls 74 62 174 116 26 5 3 460
Table S2 BC cases, PY, and incidence rates per 100,000 PY, according to menopausal status and parity
Status Parity
0 1 2 3 4 5 6
Premenopause
Cases 168 219 688 358 86 13 2
PY 7,6189 101,736 356,276 212,648 55,512 12,065 2744
Rates 220.50 215.26 193.11 168.35 154.92 107.75 72.88
Postmenopause
Cases 535 618 2082 1254 372 95 27
PY 132,262 172,437 636,545 420,991 144,901 43,189 13,662
Rates 404.50 358.39 327.08 297.87 256.73 219.97 197.62
Total
Cases 703 837 2770 1612 458 108 29
PY 20,8451 274,173 992,821 633,639 200,413 55,253 16,407
Rates 337.25 305.28 279.00 254.40 228.53 195.46 176.76
Note: Data from the entire NOWAC cohort.
Abbreviations: BC, breast cancer; NOWAC, Norwegian Women and Cancer; PY, person-years.
Table S3 Tests for linear trend between strata of risk factors
Stratification % decrease per child Intercept b Pr > |t|b
Percentage change per child
Overall 8 334.34 –26.84 <0.001
Stratified according to:
Premenopause 11 236.4 –24.86 <0.001
Postmenopause 9 398.29 –34.57 <0.001
With mother history of BC 10 631.76 –61.68 0.01
Without mother history of BC 8 317.59 –24.56 <0.001
Age at first birth <25 years 7 305.73 –22.4 0.002
Age at first birth ≥25 years 6 341.39 –20.93 0.06
BMI <25 kg/m2 9 337.08 –28.81 <0.001
BMI ≥25 kg/m2 8 333.51 –25.09 <0.001
Use of OC 6 323.64 –20.76 <0.001
No use of OC 9 340.42 –30.21 <0.001
No lactation 11 340.34 –35.78 0.022
Years of lactation: 1–2 9 340.61 –30.33 0.002
Years of lactation: 3+ 14 488.44 –68.55 0.017
HRT (only postmenopause) 9 530.49 –49.27 0.009
No HRT (only postmenopause) 9 377.31 –32.77 <0.001
Note: Data from the entire NOWAC cohort.
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Table S4 Age-adjusted and multivariate-adjusted Cox 
proportional hazard ratios and 95% CIs for BC according to 
parity in the entire NOWAC cohort
Parity BC
Crude Adjusteda
1 0.91 (0.82–1.00) 0.86 (0.77–0.96)
2 0.81 (0.75–0.88) 0.75 (0.68–0.83)
3 0.73 (0.68–0.80) 0.68 (0.61–0.76)
4 0.63 (0.56–0.71) 0.59 (0.51–0.67)
5 0.52 (0.43–0.64) 0.49 (0.39–0.62)
6+ 0.50 (0.37–0.66) 0.49 (0.36–0.68)
Note: aAdjustment for maternal history of BC (yes, no), BMI (<25, 25+ kg/m2), 
current use of hormone replacement therapy (yes, no), years of lactation (0, 1–2, 
2+), and use of oral contraceptives (ever used oral contraceptives, never used 
contraceptives).
Abbreviations: BC, breast cancer; BMI, body mass index; CI, confidence interval; 
NOWAC, Norwegian Women and Cancer.
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